Theranostics Health Inc. is a privately held company founded in 2006. Our core technologies are focused on the quantitative measurement of proteins comprising key signaling pathways in disease and include pre-analytical processing of preclinical and clinical samples, Laser Capture Microdissection (LCM), and Reverse Phase Protein Microarray (RPMA). Theranostics Health has the ability to work with both fresh frozen and formalin-preserved research and clinical samples, and is developing a set of proprietary fixatives that will preserve cellular morphology and fix the state of cellular activities for molecular analysis. LCM is used to isolate specific cell populations from the many different types of cells usually present in a clinical biopsy tissue sample. Therefore, information derived from subsequent molecular assays is specific to that targeted cell population. RPMA enables sensitive, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting materials, such as clinical specimens. Theranostics Health has an exclusive license from the National Institute of Health (NIH) to commercialize LCM isolation of cells with proteomic analysis for cancer diagnostics and companion diagnostics.
Theranostics Health is pursuing two parallel business lines. One business line focuses upon providing protein-based translational research services to drug development companies and academic institutions for biomarker and companion diagnostic purposes. Our technologies are of particular use for companies that develop molecular targeted therapies or combination therapies as they allow insights into the phospho-activation status of drug targets and receptors, their downstream pathways, and potential survival or adaptive mechanisms within targeted cell populations.
Theranostics Health is also a CAP-CLIA laboratory service provider of clinical tests that focus upon drug target and pathway signaling activation which enable physicians to tailor optimized therapies for patients based on the biomarker profile of each patient’s unique cancer proteome. Our currently available assay panel, the TheraLink™ HER Family Assay, measures the total amount and activation (phosphorylation) status of the therapeutically relevant EGFR, HER2 and HER3 receptor family, and their downstream signaling pathways in primary and metastatic breast cancers.